Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
Transient detectable viremia and the risk of viral rebound in patients from the Swiss HIV Cohort Study
BMC Infectious Diseases, Volume 15, No. 1, Article 382, Year 2015
Notification
URL copied to clipboard!
Description
Background: Temporary increases in plasma HIV RNA ('blips') are common in HIV patients on combination antiretroviral therapy (cART). Blips above 500 copies/mL have been associated with subsequent viral rebound. It is not clear if this relationship still holds when measurements are made using newer more sensitive assays. Methods: We selected antiretroviral-naive patients that then recorded one or more episodes of viral suppression on cART with HIV RNA measurements made using more sensitive assays (lower limit of detection below 50 copies/ml). We estimated the association in these episodes between blip magnitude and the time to viral rebound. Results: Four thousand ninety-four patients recorded a first episode of viral suppression on cART using more sensitive assays; 1672 patients recorded at least one subsequent suppression episode. Most suppression episodes (87%) were recorded with TaqMan version 1 or 2 assays. Of the 2035 blips recorded, 84%, 12% and 4% were of low (50-199 copies/mL), medium (200-499 copies/mL) and high (500-999 copies/mL) magnitude respectively. The risk of viral rebound increased as blip magnitude increased with hazard ratios of 1.20 (95% CI 0.89-1.61), 1.42 (95% CI 0.96-2.19) and 1.93 (95% CI 1.24-3.01) for low, medium and high magnitude blips respectively; an increase of hazard ratio 1.09 (95% CI 1.03 to 1.15) per 100 copies/mL of HIV RNA. Conclusions: With the more sensitive assays now commonly used for monitoring patients, blips above 200 copies/mL are increasingly likely to lead to viral rebound and should prompt a discussion about adherence. © 2015 Young et al.
Authors & Co-Authors
Rickenbach, Martin
Switzerland, Lausanne
Université de Lausanne Unil
Calmy, Alexandra L.
Switzerland, Geneva
Hôpitaux Universitaires de Genève
Bernasconi, Enos
Switzerland, Bellinzona
Ente Ospedaliero Cantonale
Staehelin, Cornelia
Switzerland, Bern
University of Bern
Schmid, Patrick
Switzerland, St Gallen
Kantonsspital St.gallen
Cavassini, Matthias
Switzerland, Lausanne
Centre Hospitalier Universitaire Vaudois
Battegay, Manuel
Switzerland, Basel
Universitätsspital Basel
Günthard, Huldrych F.
Switzerland, Zurich
Universitatsspital Zurich
Bucher, Heíner C.C.
Switzerland, Basel
Universitätsspital Basel
Aubert, Vincent
Unknown Affiliation
Bernasconi, Enos
Unknown Affiliation
Böni, Jürg
Unknown Affiliation
Bucher, Heiner C.
Unknown Affiliation
Burton-Jeangros, Claudine
Unknown Affiliation
Calmy, Alexandra
Unknown Affiliation
Cavassini, Matthias
Unknown Affiliation
Dollenmaier, Guenter
Unknown Affiliation
Egger, Matthias
Unknown Affiliation
Elzi, Luigia
Unknown Affiliation
Fehr, Jan Sven
Unknown Affiliation
Fellay, Jacques
Unknown Affiliation
Furrer, Hansjakob
Unknown Affiliation
Fux, Christoph Andreas
Unknown Affiliation
Gorgievski, Meri
Unknown Affiliation
Günthard, Hüldrych Fritz
Unknown Affiliation
Haerry, David Hans Ulrich
Unknown Affiliation
Hasse, Barbara Katharina
Unknown Affiliation
Hirsch, Hans H.
Unknown Affiliation
Hoffmann, Matthias
Unknown Affiliation
Hösli, Irene Mathilde
Unknown Affiliation
Kahlert, Christian R.
Unknown Affiliation
Kaiser, Laurent K.
Unknown Affiliation
Keiser, Olivia
Unknown Affiliation
Klimkait, Thomas
Unknown Affiliation
Kouyos, Roger D.
Unknown Affiliation
Kovari, Helen
Unknown Affiliation
Ledergerber, Bruno
Unknown Affiliation
Martinetti, Gladys
Unknown Affiliation
Martínez de Tejada, Begoῆa
Unknown Affiliation
Metzner, Karin Jutta
Unknown Affiliation
Müller, Nicolas J.
Unknown Affiliation
Nadal, David
Unknown Affiliation
Nicca, Dunja
Unknown Affiliation
Pantaleo, Giuseppe P.
Unknown Affiliation
Rauch, Andri
Unknown Affiliation
Regenass, Stephan
Unknown Affiliation
Rudin, Christoph
Unknown Affiliation
Schöni-Affolter, Franziska
Unknown Affiliation
Schmid, Patrick
Unknown Affiliation
Schüpbach, Jörg Rg
Unknown Affiliation
Speck, Roberto F.
Unknown Affiliation
Tarr, Philip E.
Unknown Affiliation
Telenti, Amalio
Unknown Affiliation
Trkola, Alexandra
Unknown Affiliation
Vernazza, Pietro Luigi
Unknown Affiliation
Weber, Rainer
Unknown Affiliation
Yerly, Sabine T.B.D.
Unknown Affiliation
Statistics
Citations: 29
Authors: 57
Affiliations: 8
Identifiers
Doi:
10.1186/s12879-015-1120-8
ISSN:
14712334
Research Areas
Environmental
Infectious Diseases
Study Design
Cohort Study
Study Approach
Quantitative